Business Editors and Medical/Health Writers
NEW YORK--(BW HealthWire)--Jan. 30, 2002
Innovatix, one of the fastest growing group purchasing organizations in the alternate site marketplace, announced the roll-out of a special pricing program with Roche Pharmaceuticals for the drug Kytril, for Innovatix's long term care providers.
Kytril is an anti-emetic drug indicated for the prevention of nausea and vomiting associated with chemotherapy and radiation.
"This contract provides our long term care pharmacy members with extremely competitive pricing on a drug that was not previously offered to them through group purchasing programs. The Innovatix long term care members will be especially pleased with this outstanding savings program for Kytril," explained John P. Sganga, President and CEO of Innovatix.
Established in 1993, Innovatix is a division of GNYHA Ventures, Inc., a wholly owned, for-profit subsidiary of the Greater New York Hospital Association (GNYHA). Innovatix offers alternate care providers cost savings through group purchasing contracts with pharmaceutical, medical/surgical, and office supply manufacturers. Innovatix's over 2,700 members include home infusion providers, independent medical oncologists, long-term care facilities, and ambulatory surgery centers. Innovatix can be reached toll-free at 888-258-3273, or on the Web at www.innovatix.com.
About Roche Pharmaceuticals
Hoffman-LaRoche, Inc. (Roche), based in Nutley, N.J., is the U.S. prescription drug unit of the Roche Group, a leading research-based health care enterprise that ranks among the world's leaders in pharmaceuticals, diagnostics and vitamins. Roche discovers, develops, manufactures and markets numerous important prescription drugs that enhance people's health, well-being and quality of life. Among the company's areas of therapeutic interest are: dermatology; genitourinary disease; infectious diseases, including influenza; inflammation, including arthritis and osteoporosis; metabolic diseases, including obesity and diabetes; neurology; oncology; transplantation; vascular diseases; and virology, including HIV/AIDS and hepatitis C.
For more information on the Roche pharmaceuticals business in the United States, visit the company's Web site at: http://www.rocheusa.com
COPYRIGHT 2002 Business Wire
COPYRIGHT 2002 Gale Group